EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access

Evaluation of [ 225 Ac]Ac‐PSMA‐617 vis‐a‐vis Rechallenge [ 177 Lu]Lu‐PSMA‐617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real‐World Clinical Scenario

Roopal Agrawal, Rahul V Parghane, Amit Joshi, Kumar Prabhash, Sandip Basu iD

The Prostate · 26.07.2026

DOI: 10.1002/pros.70228 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Prostate, online erschienen am 26.07.2026. Verfasst von Roopal Agrawal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, Parel, India. Hauptthemen laut MEDLINE: Actinium, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

A subset of prostate cancer progresses to aggressive state of metastatic castration‐resistant prostate cancer (mCRPC), wherein multiple therapeutic options demonstrate limited success rates. In this observational study, we aimed to evaluate the efficacy, toxicity, and survival outcomes of (a) [ 225 Ac]Ac‐PSMA‐617, (b) rechallenge [ 177 Lu]Lu‐PSMA‐617, (c) cabazitaxel, and (d) oral metronomic cyclophosphamide treatments in postdocetaxel mCRPC patients with progressive disease following initial course of [ 177 Lu]Lu‐PSMA‐617 or without previous [ 177 Lu]Lu‐PSMA‐617 PRLT (PSMA‐targeted radioligand therapy).

Methods

The study reviewed the medical records of mCRPC patients who had documented disease progression following treatment with androgen receptor pathway inhibitors and docetaxel. These patients had multiple therapeutic options and treated with [ 225 Ac]Ac‐PSMA‐617(alpha based‐PRLT) or rechallenge [ 177 Lu]Lu‐PSMA‐617 or chemotherapy with cabazitaxel or metronomic cyclophosphamide. We stratified the latter group (chemotherapy) based on prior exposure to initial course of [ 177 Lu]Lu‐PSMA‐617 as received and not received. We evaluated and analyzed the response outcomes from these therapies under five headings: (a) symptomatic response, (b) biochemical response, (c) functional and anatomical imaging response, (d) survival outcomes, and (e) toxicity profiles.

Results

A total 66 mCRPC patients were included and analyzed in this study. These patients were divided into two cohorts. Cohort 1 ( n = 49 patients) received initial course of [ 177 Lu]Lu‐PSMA‐617 and cohort 2 ( n = 17 patients) not received initial course of [ 177 Lu]Lu‐PSMA‐617. The patients were divided into arm A to F based upon treatment received as follows: Cohort 1‐ arm A ( n = 15 patients) received [ 225 Ac]Ac‐PSMA‐617, arm B ( n = 18 patients) received rechallenge [ 177 Lu]Lu‐PSMA‐617, arm C ( n = 8 patients) received cabazitaxel, arm D ( n = 8 patients) received metronomic cyclophosphamide. Cohort 2‐ arm E ( n = 14 patients) cabazitaxel and arm F ( n = 3 patients) metronomic cyclophosphamide. Patients in arm A showed favorable response outcomes in terms of symptomatic response evaluation and quality‐of‐life performance, biochemical and imaging response evaluation, with a PSA decline of > 50% and disease control rate (DCR) of 60% patients and 80% respectively. Patients treated with rechallenge [ 177 Lu]Lu‐PSMA‐617 and chemotherapy also showed modest response rates. For toxicity profiles, arm A and arm B patients had mild and manageable toxicities, contrary to arm C, D, E, and F, wherein severe clinical and hematological toxicities were observed in a significant fraction of patients. Median progressive free survival (PFS) for the overall cohort (cohort 1 and 2) was 5 months (95% CI: 4–7 months), with no significant difference across treatment arms ( p = 0.28). Median overall survival (OS) for entire cohort was 12 months (95% CI: 9–15 months) with significantly longer OS in arm A and E patients compared to other arms ( p = 0.0358).

Conclusion

Postdocetaxel mCRPC patients with progressive disease following initial course of [ 177 Lu]Lu‐PSMA‐617 when treated with [ 225 Ac]Ac‐PSMA‐617PRLT showed favorable and encouraging clinical, biochemical, and imaging response rates along with longer PFS and OS with minimal treatment‐related toxicities. Rechallenge [ 177 Lu]Lu‐PSMA‐617 and chemotherapy‐based approaches also provided clinical benefit in selected patients, reflecting the range of salvage treatment strategies employed in real‐world practice. Future large‐sized, prospective randomized trials are needed to establish the efficacy of all these treatments particularly alpha‐based PRLT in clinical practice of mCRPC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ActiniumDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantTaxoidsAgedHumansMaleAdministration, MetronomicAdministration, OralProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

PERCISTRECIPRECIST[177Lu]Lu‐PSMA‐617[225Ac]Ac‐PSMA‐617cabazitaxelchemotherapymetastatic castrate resistant prostate carcinomametronomic cyclophosphosphamidepeptide receptor radioligand therapyprogression free survival and overall survivalrechallenge [177Lu]Lu‐PSMA‐617 RLTtargeted alpha therapy

Substanzen

(225)Ac-PSMA-617ActiniumcabazitaxelDipeptidesHeterocyclic Compounds, 1-RingLutetiumlutetium (177Lu) vipivotide tetraxetanLutetium-177Prostate-Specific AntigenRadioisotopes

Autor:innen und Institutionen

  • Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, Parel, India.
  • Homi Bhabha National Institute, Mumbai, India.
  • Department of Medical Oncology, Tata Memorial Centre, Mumbai, India.

ORCID-Profile: Sandip Basu

Zitieren

APA

Agrawal, R., Parghane, R. V., Joshi, A., Prabhash, K., & Basu, S. (2026). Evaluation of [ 225 Ac]Ac‐PSMA‐617 vis‐a‐vis Rechallenge [ 177 Lu]Lu‐PSMA‐617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real‐World Clinical Scenario. The Prostate. https://doi.org/10.1002/pros.70228

Vancouver

Agrawal R, Parghane RV, Joshi A, Prabhash K, Basu S. Evaluation of [ 225 Ac]Ac‐PSMA‐617 vis‐a‐vis Rechallenge [ 177 Lu]Lu‐PSMA‐617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real‐World Clinical Scenario. The Prostate. 2026. doi:10.1002/pros.70228

BibTeX
@article{Agrawal2026,
  author = {Agrawal, Roopal and Parghane, Rahul V and Joshi, Amit and Prabhash, Kumar and Basu, Sandip},
  title = {Evaluation of [ 225 Ac]Ac‐PSMA‐617 vis‐a‐vis Rechallenge [ 177 Lu]Lu‐PSMA‐617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real‐World Clinical Scenario},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70228}
}
Kostenlos starten →